Navigation Links
Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements
Date:5/18/2011

lutions we have already brought to market, but we are also putting a stake in the ground to let our customers know that our future products will push the limits on pricing, efficiency, footprint, brightness and reliability."

Oclaro's Current and Future Fiber Laser solutions

Oclaro delivers one of the most complete portfolios of diodes for fiber laser solutions today.  These products include the following:

  • 915 to 976nm BMU single emitters - 10W from a 105um fiber.  90% of the light contained in a 0.12 NA.
  • 915 to 976nm BMU multi-emitter - 25W from a 105um fiber.  90% of the light contained in a 0.12 NA.
  • Orion VBG - 20W from a 105um fiber.  Wavelength locked at 976 nm, <-0.5 nm FWHM.  90% of the light contained in a 0.18 NA.
  • Seed Lasers - High output power, up to 400mW kink free CW or 1.2W pulsed peak at 1060nm, single mode lasers.

For future products, Oclaro intends to leverage its vast technology and manufacturing resources to continue improving the efficiency, beam strength, and reliability of its fiber laser diode offerings.  The company anticipates that future pump lasers will drive pricing to well below $10 per watt, significantly improve efficiency, reduce packaging footprint by 20 percent and increase brightness by 30 percent.   Below is a summary of the types of innovations Oclaro intends to bring to market in the future:

  • Develop higher brightness/power single emitter chips
  • Develop range of MM multi-emitter solutions to address various market segments (low and mid power)
  • Introduce super high power solutions for KW through fiber combining trays
  • Provide improved wavelength stability with gratings
  • Expand single mode seed laser portfolio to include new wavelengths and low-noise op
    '/>"/>

SOURCE Oclaro, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Oclaro Next-Generation Orion Fiber-Coupled Diode Laser Raises the Bar for Performance, Cost and Reliability for Solid State Lasers
2. Access Pharmaceuticals Provides Update on MuGard Commercial Activities
3. Lilly Provides Its Perspective in Response to Amylin Lawsuit
4. Lilly Provides Statement in Response to Amylin Lawsuit
5. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
6. Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details
7. Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
8. Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer
9. China Botanic Pharmaceutical Provides Update on Badger Oil Sales
10. Atrium Provides Grant to Establish Education Web Site at AtriumU.com
11. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 According to a ... Trauma Fixation Devices Market - Global Forecast, Market Share, ... global orthopedic trauma fixation devices market is estimated at ... grow at a CAGR of 7.2% from 2014 to ... billion in 2020. Browse the Orthopedic Trauma ...
(Date:7/29/2014)... CITY and TORONTO ... EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging ... the development of improved novel formulations and ... molecules announces expansion of its pharmaceutical development ... development direction includes large molecule drugs that will ...
(Date:7/29/2014)... VIEW, Calif. , July 29, 2014 /PRNewswire/ ... emergency response systems (PERS) market, Frost & Sullivan ... & Sullivan Award for Price Performance Value Leadership. ... usage directly captures expectations for tech progression in ... US consumers for these solutions. MobileHelp ...
Breaking Medicine Technology:Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3
... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... LLY ) and Alkermes, Inc. (Nasdaq: ... the DURATION-3 and -4 trials demonstrating patients treated ... injectable suspension) experienced significant improvements in select cardiovascular ...
... and UTRECHT, The Netherlands, September 12, 2011 ... ("Silence"), a leading global RNA interference ( RNAi ) ... company developing pathway targeted microRNA ("miRNA")-based therapeutics for cancer, ... to develop novel microRNA therapeutics for the treatment of ...
Cached Medicine Technology:Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 2Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 3Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 4Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 5Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 6Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 7Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 8Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 9Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics 2Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics 3Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics 4Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics 5Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics 6
(Date:7/29/2014)... Biocides are chemical substances, which are ... fungi growth and to prevent degradation of the physical ... its surface. It is used in various applications such ... beverage, paints and coatings. It is also used in ... as in industrial applications to prevent fouling in water ...
(Date:7/29/2014)... JOLLA, Calif. (PRWEB) July 29, 2014 ... a comprehensive overview of the hepatitis C (hep C) ... the potential of these treatments to reduce human suffering. ... understanding of the impact of hep C, while highlighting ... a new era of treatment. CHI is a nonprofit, ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Decorative contact lenses may ... careful, they can cause serious eye damage. Decorative ... ophthalmologist, according to the U.S. Food and Drug Administration ... a valid prescription for these lenses and buy them ... spread the word about the potential health risks associated ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The Transformer Oil ... market in Europe with analysis and forecast of revenue. The ... around $0.3 billion in 2013 to $0.5 billion by 2018, ... Browse through the TOC of the Transformer Oil Market in ... provided. This also provides a glimpse of the segmentation in ...
(Date:7/29/2014)... 29, 2014Today the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) ... partnership to improve access to essential pain medications for ... of ACS, Treat the Pain initiative, this new partnership ... into HIV/AIDS services throughout the country. , Swaziland ... more than 26 percent of adults ages 15-49 infected. ...
Breaking Medicine News(10 mins):Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 2Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 3Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 4Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 2Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 3Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 4Health News:It's 'Buyer Beware' for Decorative Contact Lenses, FDA Says 2Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:New partnership to improve access to essential pain medications for people living with HIV 2
... 26 You know that the HPV (human,papillomavirus) ... Is there a,theoretical basis for exploring its use ... a 3-part CME Webcast, assesses this,and other issues ... online,offering from Sexuality, Reproduction and Menopause (SRM), a ...
... combative kids , , TUESDAY, Feb. 26 (HealthDay News) -- For ... biological reason for all the family feuding -- adolescent brain ... when key regions of the brain known for controlling emotions ... and more persistent during their fights with Mom and Dad. ...
... 26 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) ... M.D. vice president of clinical research. In this ... the direction and,oversight of Rigel,s clinical research programs ... R788, oral syk kinase,inhibitor, is expected to enter ...
... Quality Cardiology Center Seeks End to Soaring Health Costs, ... Hospital,one of the nation,s leading cardiology treatment centers, announced ... for one of the most common types of,open heart ... Wichita,Eagle published this week. "After carefully studying our costs ...
... 26 EntreMed, Inc.,(Nasdaq: ENMD ) a ... cancer and inflammatory diseases, today,announced that James S. ... Corporate overview at the Jesup & Lamont Emerging ... Disney Contemporary Resort in,Orlando, Florida on Thursday, February ...
... Lt. Gov. David A. Paterson, along with stem cell experts Arnold ... will be the keynote speakers at the 3rd Annual Stem Cell ... Hilton New York ... 1335 Avenue of the Americas, WHAT: Largest gathering of stem ...
Cached Medicine News:Health News:Experts Delve Into Issues of HPV Vaccination 2Health News:Teen Aggression May Really Be a State of Mind 2Health News:Teen Aggression May Really Be a State of Mind 3Health News:Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research 2Health News:Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research 3Health News:EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference 2Health News:MEDIA ADVISORY: New York Lt. Gov. David Paterson and Stem Cell Experts to Participate in 3rd Annual Stem Cell Summit 2
... Davis's Drug Guide 10th ... Updates include 200 new drug ... indexes and a new Bookmark ... answers you need. Includes PDA, ...
Davis's Drug Guide for Nurses - now with over 760 Integrated Calculators - combines the most comprehensive, up-to-date and practical drug resource with built in drug dosing calculation tools for most...
... The Concise Guide to Drug Interaction Principles ... written expressly for clinicians. , An understanding ... the practice of medicine. Since publication of ... in 2001, our increasing pharmacopoeia - coupled ...
Clinician's Pocket Drug Reference 2005 includes key elements of commonly used medications that are essential information for both the student and practicing physician....
Medicine Products: